Protective effects of interleukin-6 in lipopolysaccharide (LPS)-induced experimental endotoxemia are linked to alteration in hepatic anti-oxidant enzymes and endogenous cytokines

Immunobiology

Volumn 215, Issue 6, 2010, Pages 443-451

  Nandi, Debolina ^a   Mishra, Manoj Kumar ^b   Basu, Anirban ^b   Bishayi, Biswadev ^a  

^a UNIVERSITY OF CALCUTTA   (India)

^b NATIONAL BRAIN RESEARCH CENTRE   (India)

Author keywords

Anti oxidant enzymes; Cytokine; Endotoxemia; Lipopolysaccharide; Reactive oxygen species

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CATALASE; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NITRIC OXIDE; RECOMBINANT INTERLEUKIN 6; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENDOTOXEMIA; ENZYME ACTIVITY; ENZYME INDUCTION; IMMUNOMODULATION; IN VIVO STUDY; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION;

ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; ENDOTOXEMIA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; NEUTROPHILS; PEROXIDASE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952551188     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2009.08.003     Document Type: Article

References (65)

1. Aebi H. Catalase in vitro: In Methods of enzymatic analysis 1974, Academic press, New York, pp. 121-125. 105th ed.
2. Ando H., Takamura T., Ota T., Nagai Y., Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J. Pharmacol. Exp. Ther. 2000, 294:1043-1046.
3. Barton B.E., Jackson J.V. Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect. Immun. 1993, 61:1496-1499.
4. Bethin K.E., Vogt S.K., Muglia L.M. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. PNAS 2000, 97(16):9317-9322.
5. Bos A., Weaver R., Roos D. Characterization and quantification of the peroxidase in human neutrophil. Biochem. Biophys. Acta 1990, 525:4133-4141.
6. Bultinck J., Sips P., Vakaet L., Brouckaert P., Cauwels A. Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock. FASEB J. 2006, 20:E1619-E1627.
7. Casey L.C., Balk R.A., Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Immunology 2002, 105:344-349.
8. Chadda K., Annane D. The use of corticosteroids in severe sepsis and acute respiratory distress syndrome. Ann. Med. 2002, 34:582-589.
9. Chrousos G.P. The hypothalamic-pituitary adrenal axis and immune mediated inflammation. N. Engl. J. Med. 1995, 332:1351-1362.
10. Cuzzocrea S., Sarro G.D., Costantino G., Ciliberto G., Mazzon E., Sarro A.D., Caputi A.P. IL-6 knock-out mice exhibit resistance to splanchnic artery occlusion shock. J. Leukoc. Biol. 1999, 66:471-480.
11. Dalrymple S.A., Slattery R., Aud D.M., Krishna M., Lucian L.A., Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect. Immun. 1996, 64:3231-3235.
12. Damas P., Ledoux D., Nys M., Vrindts Y., De Groote D., Franchimont P., Lamy M. Cytokine serum levels during severe sepsis in human: IL-6 as a marker of severity. Ann. Surg. 1992, 215:362-365.
13. Das, D., Das, A., 2005. Analysis of variance. In: Das, D. (Ed.), Statistics in Biologyand Psychology, fifth ed., Academic Publisher, Calcutta, pp. 280-293 (Chapter 11).
14. Doherty G.M., Lange J.R., Langstein H.N., Alexander H.R., Burech C.M., Norton J.A. Evidence for IFN-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J. Immunol. 1992, 149:1666-1670.
15. Dutta K., Bishayi B. Escherichia coli lipopolysaccharide (LPS) administration alters antioxidant profile during hypercholesterolemia. Ind. J. Clin. Biochem. 2009, 24(2):179-183.
16. Dutta K., Nandi D., Bishayi B. Repeated systemic Escherichia coli infection enhances anti-oxidant response in hypercholesterolemic mice inducing cardiovascular inflammation. Inflammation 2009, 32:89-98.
17. Franchimont D., Bouma G., Galon J., Wolkersdörfer G., Haidan A., Chrousos G., Bornstein S. Adrenal cortical activation in murine colitis. Gastroenterology 2000, 119:1560-1568.
18. Gardlund B., Sjolin J., Nilsson A., Roll M., Wickerts C., Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J. Infect. Dis. 1995, 172:296-301.
19. Gazzinelli R.T., Eltoum I., Wynn T.A., Sher A. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-a and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J. Immunol. 1993, 151:3672-3681.
20. Ghosal A., Das S., Ghosh S., Mishra M.K., Sharma V., Koli P., Sen E., Basu A. Pro-inflammatory mediators released by activated microglia induces neuronal death in Japanese Encephalitis. Glia 2007, 55:483-496.
21. Green S.J., Nacy C.A., Schreiber R.D., Granger D.I., Crawford R.M., Meltzer M.S., Fortier A.H. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from l-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect. Immun. 1993, 61:689-698.
22. Han S.H., Meydani S.N. Anti-oxidants, cytokines and influenza infection in aged mice and elderly humans. J. Infect. Dis. 2000, 182(Suppl. 1):S74-S80.
23. Heinzel F.P. The role of IFN-gamma in the pathology of experimental endotoxemia. J. Immunol. 1990, 145:2920-2924.
24. Heremans H., Dillen C., Put W., Damme Van J., Billiau A. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur. J. Immunol. 1992, 22:2395-2401.
25. Heremans H.J., van Damme C., Dijkmans D.R., Billiau A. Interferon-γ, a mediator of lethal lipopolysaccharide-induced Schwarzman like shock reactions in mice. J. Exp. Med. 1990, 171:1853-1869.
26. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin. Immunol. Immunopathol. 1992, 62:S60-S65.
27. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 2003, 348:138-150.
28. Klosterhalfen B., Horstmann-Jungemann K., Vogel P., Flohe S., Offner F. Time course of various inflammatory mediators during recurrent endotoxemia. Biochem. Pharmacol. 1992, 43:2103-2109.
29. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 24:339-342.
30. Lee J.S., Bok S.H., Park Y.B., Lee M.K., Choi M.S. 4-Hydroxycinnamate lowers plasma and hepatic lipids without changing antioxidant enzyme activities. Ann. Nutr. Metab. 2003, 47:144-151.
31. Liew F.Y. Regulation of nitric oxide synthesis in infectious and autoimmune diseases. Immunol. Lett. 1994, 43:95-98.
32. Madan M., Bishayi B., Hoge M., Amar S. Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model. Atherosclerosis 2008, 197(2):504-514.
33. Manthey C.L., Vogel S.N. The role of cytokines in the host response to endotoxin. Rev. Med. Microbiol. 1992, 3:72.
34. Marchant A., Bruyns C., Vandenabeele P., Ducarme M., Gerard C., Delvaux A., DeGroote D., Abramowicz D., Velu T., Goldman M. Interleukin-10 controls interferon-g and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 1994, 4:1167-1171.
35. Martich G.D., Boujoukos A.J., Suffredini A.F. Response of man to endotoxin. Immunobiology 1993, 187:403-416.
36. Minnard E.A., Shou J., Naama H., Cech A., Gallagher H., Daly J.M. Inhibition of nitric oxide synthesis is detrimental during endotoxemia. Arch. Surg. 1994, 129:142.
37. Nelson Determination of blood glucose. J. Biol. Chem. 1944, 153-375.
38. Newton R.C., Decicco C.P. Therapeutic potential and strategies for inhibiting tumor necrosis factor alpha. J. Med. Chem. 1999, 42(13):2295-2314.
39. Panillo I.E. Pathogenic mechanisms of septic shock. N. Engl. J. Med. 1993, 328:1471.
40. Parmely M.J., Fuan W., Wright D. Gamma Interferon prevents the inhibitory effects of oxidative stress of host responses to Escherichia coli infection. Infect. Immun. 2001, 69:2621-2629.
41. Plummer D.T. An Introduction to Practical Biochemistry 1999, Tata McGraw-Hill Publication Company, pp. 182-185.
42. Preiser J.C., Schmartz D., Van der Linden P., Content J., Vanden Bussche P., Buurman W., Sebald W., Dupont E., Pinsky M.R., Vincent J.L. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine 1991, 3:1-4.
43. Reitmen S., Frankel A. A colorimetric method for the determination of serum glutamate oxaloacetate and serum glutamate pyruvate transaminase. Am. J. Clin. Pathol. 1957, 28:56-57.
44. Salkowski C.A., Detore G., Mcnally R., Rooijen Nvan., vogel S.N. Regulation of inducible nitric oxide production by lipopolysaccharide in vivo: the roles of macrophages, endogenous IFN-gamma, and TNF receptor-1 mediated signaling. J. Immunol. 1997, 158:905-912.
45. Salkowski C.A., Neta R., Wynn T.A., Strassmann G., Rooijen Nvan., Vogel S.N. Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection. J. Immunol. 1995, 155:3168.
46. Silverstein R., Johnson D.C. Endogenous versus exogenous glucocorticoid responses to experimental bacterial sepsis. J. Leukoc. Biol. 2003, 73:417-427.
47. Smith A.L. Treatment of septic shock with immunotherapy. Pharmacotherapy 1998, 18:565-580.
48. Somogyi Determination of blood glucose. J. Biol. Chem. 1945, 62:160.
49. Spath-Schwalbe E., Born J., Schrezenmeier H. Interleukin-6 stimulates the hypothalamus pituitary adrenocortical axis in man. J. Clin. Endocrinol. Metab. 1994, 79:1212-1214.
50. Standiford T.J., Strieter R.M., Lukacs N.W., Kunkel S.L. Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol. 1995, 155:2222-2229.
51. Starnes H.F.J., Pearce M.K., Tewari A., Yim J.H., Zou J.C., Abrams J.S. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-a challenge in mice. J. Immunol. 1990, 145:4185-4191.
52. Steege, J.C.A. ter., Monique, W.C.M. van de Ven., Forget, P.Ph., Brouckaert, P., Buurman, W.A., 1998. The role of endogenous IFN-γ, TNF-α and IL-9 in LPS induced nitrtic oxide release in a mouse model. Cytokine 10, 115-123.
53. Straub R.H., Schuldl A., Mullington J., Haackl M., Schölmerich J., Pollmächer T. The endotoxin-induced increase of cytokines is followed by an increase of cortisol relative to dehydroepiandrosterone (DHEA) in healthy male subjects. J. Endocrinol. 2002, 175:467-474.
54. Takagi K., Hosaka T., Suketa Y. Effect of recombinant human interleukin-6 on nitrite production of mouse myeloid leukemia cells. J. Cell Physiol. 2005, 147(2):306-310.
55. Tilg H., Trefu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 as an anti-inflammatory cytokine: induction of circulating Interleukin-1 receptor antagonist and soluble tumor necrosis factor receptor. Blood 1994, 83:113-118.
56. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., Lowry S.F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature (London) 1987, 330:662-664.
57. Ulloa L., Tracey K.J. The 'cytokine profile': a code for sepsis. Trends Mol. Med. 2005, 11:56-63.
58. Ulrich T.R., Guo K.Z., Irwin B., Remick D.G., Davatells G.N. Endotoxin induced cytokine gene expression in vivo: II Regulation of tumor necrosis factor and interleukin-1α/Β expression and suppression. Am. J. Pathol. 1990, 137:1173-1185.
59. Van der meer J.W.M., Helle M., Aarden L. Comparison of the effect of recombinant interleukin-6 and recombinant interleukin-1 on nonspecific resistance to infection. Eur. J. Immunol. 1981, 19:413-416.
60. Van der Poll T., Levi M., Hack C.E., Cate H., Deventer S.J., Eerenberg A.J., Groot E.R., Jansen J., Gallati H., Buller H.R. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med. 1994, 179:1253-1259.
61. Visner G.A., Dougall W.C., Wilson J.M., Burr I.A., Nick H.S. Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin- 1, and tumor necrosis factor: role in the acute inflammatory response. J. Biol. Chem. 1990, 265:2856-2864.
62. Walley K.R., Lukacs N.W., Standiford T.J., Strieter R.M., Kunkel S.L. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect. Immun. 1996, 64:4733-4738.
63. Wong G.H., Goeddel D.V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 1988, 242:941-944.
64. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., Achong M.K. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 1998, 101:311-320.
65. Yoshimoto T., Nakanishi K., Hirose S., Hiroishi K., Okamura H., Takemoto Y., Kanamaru A., Hada T., Tamura T., Kakishita E., Higashino K. High serum IL-6 level reflects susceptible status of the host to endotoxin and IL-1/tumor necrosis factor. J. Immunol. 1992, 148:3596-3603.